Acurx announces positive phase 2b results showing 100% of patients who had clinical cure with ibezapolstat also had sustained clinical cure

All 15 ibezapolstat-treated patients in phase 2b who achieved clinical cure (cc) at end of treatment (eot) remained free of c. difficile infection (cdi) recurrence through one month after eot, for a sustained clinical cure (scc) rate of 100%  2 of 14 patients treated with standard of care, oral vancomycin, experienced recurrent infection within one month after eot for a scc of 86% 100% of the 25 ibezapolstat-treated patients in phase 2 (phase 2a and 2b) who had cc at eot remained cured through one month after eot further analyses will be forthcoming q1 2024, as data become available, regarding other endpoints, from the phase 2b trial, including extended clinical cure (ecc) data up to 94 days and comparative effects vs vancomycin on the gut microbiome preparation underway for meetings with fda, european medicines agency and other global regulatory agencies and advancement to international phase 3 clinical trials staten island, n.y.
ACXP Ratings Summary
ACXP Quant Ranking